Vor Historical Balance Sheet

VOR Stock

USD 0.87 0.02 2.35%

Trend analysis of Vor Biopharma balance sheet accounts such as Total Assets of 152.4 M, Short Long Term Debt Total of 27 M, Other Current Liabilities of 6.8 M or Total Current Liabilities of 12.2 M provides information on Vor Biopharma's total assets, liabilities, and equity, which is the actual value of Vor Biopharma to its prevalent stockholders. By breaking down trends over time using Vor Biopharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Vor Biopharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Vor Biopharma is a good buy for the upcoming year.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vor Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

To learn how to invest in Vor Stock, please use our How to Invest in Vor Biopharma guide.

About Vor Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Vor Biopharma at a specified time, usually calculated after every quarter, six months, or one year. Vor Biopharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Vor Biopharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Vor currently owns. An asset can also be divided into two categories, current and non-current.

Vor Biopharma Balance Sheet Chart

At this time, Vor Biopharma's Accumulated Other Comprehensive Income is relatively stable compared to the past year. As of 03/23/2025, Net Working Capital is likely to grow to about 105.1 M, while Other Current Liabilities is likely to drop slightly above 6.8 M.

Total Assets Short Long Term Debt Total Other Current Liab Cash Non Current Assets Total

Add Fundamental

Total Assets

Total assets refers to the total amount of Vor Biopharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Vor Biopharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Cash

Cash refers to the most liquid asset of Vor Biopharma, which is listed under current asset account on Vor Biopharma balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Vor Biopharma customers. The amounts must be unrestricted with restricted cash listed in a different Vor Biopharma account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.

Non Current Assets Total

The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.

Most accounts from Vor Biopharma's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Vor Biopharma current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vor Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

To learn how to invest in Vor Stock, please use our How to Invest in Vor Biopharma guide.At this time, Vor Biopharma's Accumulated Other Comprehensive Income is relatively stable compared to the past year. As of 03/23/2025, Net Working Capital is likely to grow to about 105.1 M, while Other Current Liabilities is likely to drop slightly above 6.8 M.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	38.9M	35.7M	31.8M	27.0M
Total Assets	299.4M	198.1M	142.9M	152.4M

Short Long Term Debt Total Total Assets

Vor Biopharma balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt
Total Assets		0.88	0.66	0.7	1.0	0.87	0.92	0.79	-0.66	-0.72	0.76	0.84	0.93	0.99	0.76	0.92	0.97	0.9	0.89	0.94	0.9	-0.28	0.99	-0.02	0.99	0.23
Short Long Term Debt Total	0.88		0.81	0.74	0.85	0.85	0.96	0.9	-0.47	-0.85	0.78	0.68	0.97	0.83	0.93	0.96	0.81	0.9	0.93	0.75	0.96	-0.41	0.83	0.1	0.82	0.04
Other Current Liab	0.66	0.81		0.92	0.6	0.78	0.83	0.76	-0.48	-0.9	0.65	0.67	0.84	0.59	0.91	0.85	0.64	0.86	0.89	0.52	0.86	-0.49	0.59	0.11	0.57	-0.07
Total Current Liabilities	0.7	0.74	0.92		0.64	0.81	0.85	0.57	-0.42	-0.86	0.56	0.63	0.84	0.64	0.74	0.85	0.69	0.87	0.91	0.62	0.87	-0.46	0.64	-0.07	0.61	0.3
Total Stockholder Equity	1.0	0.85	0.6	0.64		0.85	0.88	0.77	-0.68	-0.67	0.75	0.84	0.89	1.0	0.72	0.88	0.97	0.87	0.85	0.95	0.86	-0.25	1.0	-0.04	1.0	0.23
Net Tangible Assets	0.87	0.85	0.78	0.81	0.85		0.86	0.69	-0.61	-0.93	0.57	0.75	0.86	0.84	0.8	0.85	0.89	0.95	0.87	0.87	0.88	-0.62	0.84	-0.3	0.83	0.32
Property Plant And Equipment Net	0.92	0.96	0.83	0.85	0.88	0.86		0.81	-0.46	-0.84	0.76	0.71	1.0	0.87	0.86	1.0	0.85	0.93	0.99	0.81	1.0	-0.36	0.87	0.06	0.86	0.2
Current Deferred Revenue	0.79	0.9	0.76	0.57	0.77	0.69	0.81		-0.66	-0.72	0.89	0.8	0.83	0.75	0.94	0.84	0.76	0.77	0.79	0.61	0.81	-0.34	0.76	0.35	0.75	-0.33
Net Debt	-0.66	-0.47	-0.48	-0.42	-0.68	-0.61	-0.46	-0.66		0.51	-0.72	-0.95	-0.49	-0.69	-0.55	-0.5	-0.76	-0.56	-0.5	-0.59	-0.46	0.42	-0.7	-0.13	-0.7	0.16
Retained Earnings	-0.72	-0.85	-0.9	-0.86	-0.67	-0.93	-0.84	-0.72	0.51		-0.61	-0.66	-0.84	-0.66	-0.87	-0.84	-0.72	-0.89	-0.87	-0.64	-0.87	0.75	-0.67	0.11	-0.64	-0.14
Accounts Payable	0.76	0.78	0.65	0.56	0.75	0.57	0.76	0.89	-0.72	-0.61		0.82	0.78	0.74	0.77	0.8	0.71	0.63	0.77	0.52	0.74	-0.35	0.74	0.57	0.74	-0.26
Cash	0.84	0.68	0.67	0.63	0.84	0.75	0.71	0.8	-0.95	-0.66	0.82		0.73	0.85	0.72	0.74	0.9	0.77	0.73	0.74	0.7	-0.38	0.85	0.13	0.84	-0.06
Non Current Assets Total	0.93	0.97	0.84	0.84	0.89	0.86	1.0	0.83	-0.49	-0.84	0.78	0.73		0.88	0.88	1.0	0.86	0.93	0.99	0.81	1.0	-0.36	0.88	0.08	0.87	0.16
Cash And Short Term Investments	0.99	0.83	0.59	0.64	1.0	0.84	0.87	0.75	-0.69	-0.66	0.74	0.85	0.88		0.7	0.87	0.98	0.86	0.84	0.95	0.85	-0.25	1.0	-0.05	1.0	0.25
Common Stock Shares Outstanding	0.76	0.93	0.91	0.74	0.72	0.8	0.86	0.94	-0.55	-0.87	0.77	0.72	0.88	0.7		0.88	0.73	0.86	0.87	0.6	0.88	-0.47	0.7	0.18	0.69	-0.22
Non Current Liabilities Total	0.92	0.96	0.85	0.85	0.88	0.85	1.0	0.84	-0.5	-0.84	0.8	0.74	1.0	0.87	0.88		0.85	0.92	0.99	0.79	0.99	-0.37	0.87	0.12	0.86	0.15
Other Current Assets	0.97	0.81	0.64	0.69	0.97	0.89	0.85	0.76	-0.76	-0.72	0.71	0.9	0.86	0.98	0.73	0.85		0.91	0.84	0.96	0.85	-0.33	0.98	-0.15	0.97	0.27
Other Stockholder Equity	0.9	0.9	0.86	0.87	0.87	0.95	0.93	0.77	-0.56	-0.89	0.63	0.77	0.93	0.86	0.86	0.92	0.91		0.94	0.87	0.95	-0.42	0.86	-0.2	0.85	0.26
Total Liab	0.89	0.93	0.89	0.91	0.85	0.87	0.99	0.79	-0.5	-0.87	0.77	0.73	0.99	0.84	0.87	0.99	0.84	0.94		0.77	0.99	-0.4	0.84	0.08	0.82	0.19
Net Invested Capital	0.94	0.75	0.52	0.62	0.95	0.87	0.81	0.61	-0.59	-0.64	0.52	0.74	0.81	0.95	0.6	0.79	0.96	0.87	0.77		0.8	-0.22	0.95	-0.34	0.95	0.44
Property Plant And Equipment Gross	0.9	0.96	0.86	0.87	0.86	0.88	1.0	0.81	-0.46	-0.87	0.74	0.7	1.0	0.85	0.88	0.99	0.85	0.95	0.99	0.8		-0.39	0.85	0.03	0.84	0.2
Short Long Term Debt	-0.28	-0.41	-0.49	-0.46	-0.25	-0.62	-0.36	-0.34	0.42	0.75	-0.35	-0.38	-0.36	-0.25	-0.47	-0.37	-0.33	-0.42	-0.4	-0.22	-0.39		-0.25	0.11	-0.24	-0.08
Total Current Assets	0.99	0.83	0.59	0.64	1.0	0.84	0.87	0.76	-0.7	-0.67	0.74	0.85	0.88	1.0	0.7	0.87	0.98	0.86	0.84	0.95	0.85	-0.25		-0.05	1.0	0.24
Capital Stock	-0.02	0.1	0.11	-0.07	-0.04	-0.3	0.06	0.35	-0.13	0.11	0.57	0.13	0.08	-0.05	0.18	0.12	-0.15	-0.2	0.08	-0.34	0.03	0.11	-0.05		-0.05	-0.7
Net Working Capital	0.99	0.82	0.57	0.61	1.0	0.83	0.86	0.75	-0.7	-0.64	0.74	0.84	0.87	1.0	0.69	0.86	0.97	0.85	0.82	0.95	0.84	-0.24	1.0	-0.05		0.24
Short Term Debt	0.23	0.04	-0.07	0.3	0.23	0.32	0.2	-0.33	0.16	-0.14	-0.26	-0.06	0.16	0.25	-0.22	0.15	0.27	0.26	0.19	0.44	0.2	-0.08	0.24	-0.7	0.24

Click cells to compare fundamentals

Vor Biopharma Account Relationship Matchups

Vor Biopharma balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	75.9M	242.6M	299.4M	198.1M	142.9M	152.4M
Other Current Liab	6.1M	4.9M	4.8M	10.9M	12.9M	6.8M
Total Current Liabilities	10.2M	10.2M	13.1M	15.6M	18.6M	12.2M
Total Stockholder Equity	48.3M	216.3M	250.6M	150.7M	96.7M	120.0M
Net Tangible Assets	(17.4M)	(59.1M)	216.3M	250.6M	288.2M	302.6M
Property Plant And Equipment Net	21.8M	22.5M	57.1M	50.1M	41.6M	30.5M
Net Debt	(30.2M)	(101.8M)	(18.8M)	4.3M	(50.1M)	(47.6M)
Retained Earnings	(61.2M)	(130.1M)	(222.2M)	(340.1M)	(457.0M)	(434.1M)
Accounts Payable	2.4M	1.5M	1.8M	815K	1.5M	1.4M
Cash	48.5M	119.8M	57.7M	31.4M	81.9M	54.5M
Non Current Assets Total	26.8M	28.2M	62.4M	57.3M	46.4M	35.1M
Cash And Short Term Investments	48.5M	207.5M	230.2M	137.2M	91.9M	113.6M
Common Stock Shares Outstanding	37.1M	37.2M	39.6M	67.2M	68.7M	46.0M
Liabilities And Stockholders Equity	75.9M	242.6M	299.4M	198.1M	142.9M	152.4M
Non Current Liabilities Total	17.4M	16.2M	35.6M	31.8M	27.6M	20.3M
Other Current Assets	567K	6.9M	6.7M	3.6M	4.6M	3.6M
Other Stockholder Equity	2.2M	346.4M	473.6M	490.9M	553.6M	293.4M
Total Liab	27.6M	26.3M	48.8M	47.4M	46.2M	32.4M
Net Invested Capital	(59.1M)	216.3M	250.6M	150.7M	96.7M	99.9M
Property Plant And Equipment Gross	21.8M	24.6M	61.7M	58.2M	52.8M	34.6M
Total Current Assets	49.1M	214.4M	237.0M	140.8M	96.5M	117.3M
Capital Stock	25.1M	107.3M	4K	7K	13K	12.4K
Net Working Capital	38.9M	204.2M	223.8M	125.2M	77.9M	105.1M
Property Plant Equipment	728K	21.8M	6.9M	12.6M	14.5M	9.3M
Non Currrent Assets Other	3.4M	3.3M	2.9M	7.2M	4.8M	4.2M

Additional Tools for Vor Stock Analysis

When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Vor Historical Balance Sheet

About Vor Balance Sheet Analysis

Vor Biopharma Balance Sheet Chart

Total Assets

Cash

Non Current Assets Total

Vor Biopharma balance sheet Correlations

Vor Biopharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Vor Biopharma balance sheet Accounts

Additional Tools for Vor Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity
Net Working Capital	+ 1.0	Total Stockholder Equity
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Non Current Liabilities Total	+ 1.0	Property Plant And Equipment Net

Cash	- 0.95	Net Debt
Retained Earnings	- 0.93	Net Tangible Assets
Retained Earnings	- 0.9	Other Current Liab
Other Stockholder Equity	- 0.89	Retained Earnings
Property Plant And Equipment Gross	- 0.87	Retained Earnings
Total Liab	- 0.87	Retained Earnings